G. Buccheri (Cuneo, Italy), A. Meert (Brussels, Belgium)
Autofluorescence (SAFE) bronchoscopy and p21/ki-67 immunostaining utilizing to distinguish areas of particular attention related to carcinogenesis. Preliminary report
|  |
Karyometric analysis of pulmonary neuroendocrine tumors
Z. Z. Mijovic, D. D. Dimov, D. S. Mihailoovic (Nis, Yugoslavia)
| |
The effects of erdosteine and caffeic acid phenethyl ester on the activities of some metabolic enzymes after cisplatin-induced nephrotoxicity in rats
H. R. Yilmaz, S. Sogut, H. Ozyurt, M. Iraz, Z. Yildirim, O. Akyol (Malatya, Turkey)
| |
Mutant P53 expression in squamous cell lung cancer
B. Salepci, N. Ozdemir, B. Caglayan, T. Salepci, S. Ozdogan, S. Erim (Istanbul, Turkey)
| |
The presence of Helicobacter pylori in tumor-free samples of bronchial biopsies of patients with lung cancer
E. Tabakoglu, S. Altaner, G. Altiay, O. N. Hatipoglu, T. Caglar (Edirne, Turkey)
| |
Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer
C. Ozturk, C. E. Kirisoglu, N. Akyurek, L. Memis (Ankara, Turkey)
| |
Nuclear and microenvironment interactions could be useful biological prognostic markers for adjuvant therapy in advanced non-small cell lung carcinoma
H. Minamoto, L. Antonangelo, C. Gallo, A. Pereira, P. H. N. Saldiva, O. Ribeiro, V. L. Capelozzi (Sao Paulo, Brazil)
| |
Distribution of BCL-2 gene expression and its prognostic value in non-small cell pulmonary cancer
A. Yilmaz, I. Savas, S. D. Sak, A. Güngör, E. Serinsoz, B. Savas (Ankara, Turkey)
| |
Prognostic significance of plasma D-dimer (DD) in lung cancer
D. Ferrigno, M. C. Giordano, G. Buccheri (Cuneo, Italy)
| |
Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer
D. Ferrigno, M. C. Giordano, G. Buccheri (Cuneo, Italy)
| |
Clinical value of measurements of interleukin-2 soluble receptor in blood of lung cancer patients
J. Szopinski, E. Roginska, E. Rogala, E. Rowinska-Zakrzewska, K. Roszkowski (Warsaw, Poland)
| |
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC)
J. Zych, M. Szturmowicz, A. Sakowicz, M. Zaleska, E. Radzikowska, J. Zaleska, E. Rowinska-Zakrzewska (Warsaw, Poland)
| |
Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC)
D. Ferrigno, M. C. Giordano, G. Buccheri (Cuneo, Italy)
| |
Prognostic and predictive value of cytokeratin-19 fragments (Cyfra 21-1), carcinoembryonic antigen (CEA) and human chorionic gonadotropin (bHCG) in 138 NSCLC patients - 5 years of observation
M. Szturmowicz, J. Zych, P. Rudzinski, A. Sakowicz, E. Rowinska-Zakrzewska (Warsaw, Poland)
| |
The effects of TNF-α combined with VP16 on growth and cell cycle of lung cancer cell line and the adhesive molecules
J. A. Huang, L. D. Zhang, J. Y. Ma, G. J. Wang, G. H. Yu, X. G. Zhang (Suzhou, China)
| |
Protective effect of oral erdostein administration on cisplatin-induced nephrotoxicity in rats
Z. Yildirim, S. Sogut, M. Iraz, H. Ozyurt, M. Kotuk, O. Akyol (Malatya, Turkey)
| |
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
L. M. Tavanti, M. Serranori, M. Luperini, S. Petruzzelli (Pisa, Italy)
| |
Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer
W. Naumnik, E. Chyczewska (Bialystok, Poland)
| |
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)?
M. Zaleska, J. Zych, A. Sakowicz, M. Szturmowicz, B. Roszkowska, E. Rowinska-Zakrzewska (Warsaw, Poland)
| |
The prognostic value of the expression of GST-π in response to chemotherapy in cytological and pathological specimens of patients with lung cancer
G. S. Vlachogeorgos, D. M. Mermigkis, E. D. Manali, E. P. Blana, S. A. Legaki, N. A. Karagiannidis, C. S. Roussos, V. S. Polychronopoulos (Athens, Greece)
| |